News | Heart Valve Technology | June 02, 2021

LivaNova Sells Heart Valve Business to Gyrus Capital

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1 to Gyrus Capital and Corcym..

The LivaNova Percelval sutureless aortic valve and Solo Smart surgical aortic valve are part of heart valve portfolio the company sold off June 1.


June 2, 2021 – LivaNova announced June 1 it successfully completed the initial closing of the divestiture of its heart valve business to the investment firm Gyrus Capital for €60 million ($73 million). Corcym, an independent company recently launched and owned by entities funded and controlled by Gyrus, will manage the heart valve business.

“The completion of the heart valve sale to Gyrus Capital allows LivaNova to optimize its portfolio and sharpen its focus on cardiovascular and neuromodulation, our two areas of excellence,” said Damien McDonald, CEO of LivaNova. “We are now better positioned to accelerate growth in our core, dedicate resources toward executing promising pipeline opportunities, and enhance our operational excellence to best serve our patients and deliver maximum value to shareholders.”

The LivaNova heart valve business consists of a comprehensive portfolio of products, featuring Perceval, a unique sutureless aortic valve, and Memo 4D, a semi-rigid mitral annuloplasty ring. Together with mechanical valves, this portfolio fits the differing needs of cardiac surgeons and patients. Approximately 850 employees will transition to Corcym as part of the global heart valve business, which has major operations in Saluggia, Italy and Vancouver, Canada. 

In the initial closing, Corcym acquired LivaNova manufacturing facilities in Saluggia and Vancouver and related assets in other geographies, representing most of the heart valve business. During the course of 2021, the parties expect to complete the transfer of the commercial operations in various local jurisdictions.

LivaNova expected the heart valve business to generate net revenues of approximately $70 million during the period of June 1 through Dec. 31, 2021. After excluding these estimated net revenues for the heart valve business, LivaNova full-year 2021 worldwide sales growth on a constant-currency basis is expected to be 0% to 5%. In addition, the company estimates an adjusted earnings per share dilution of approximately $0.09 related to the divestiture, and now anticipates full-year 2021 adjusted earnings per share of $1.31 to $1.81. Adjusted free cash flow will exclude proceeds received from the divestiture. LivaNova will provide further details on the financial impact of the divestiture when it reports its second-quarter 2021 results.
 
For more information: www.livanova.com
 
 

Related Content

News | Cardiovascular Surgery

November 23, 2021 — A novel device called venous external support (VEST) may lead to increased longevity and durability ...

Home November 23, 2021
Home
News | Cardiovascular Surgery

November 22, 2021 — The Minneapolis Heart Institute Foundation (MHIF) announced the publication of research showing ...

Home November 22, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — Moderna Inc. announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating ...

Home November 18, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — People who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may ...

Home November 18, 2021
Home
Feature | Cardiovascular Surgery | By Noam Emanuel, Ph.D.

Surgical Site Infection (SSI) prevention remains a high priority for cardiac surgeons whose heroic efforts can be ...

Home June 24, 2021
Home
News | Cardiovascular Surgery

April 5, 2021 — Smidt Heart Institute transplant surgeons Dominic Emerson, M.D., and Pedro Catarino, M.D. know how to be ...

Home April 05, 2021
Home
News | Cardiovascular Surgery

March 30, 2020 — Patients undergoing coronary bypass graft (CAGB) surgery lived longer and had better outcomes when ...

Home March 30, 2020
Home
News | Cardiovascular Surgery

February 27, 2020 — The U.S. Food and Drug Administration (FDA) sent a safety communication this week to healthcare to ...

Home February 27, 2020
Home
News | Cardiovascular Surgery

October 23, 2019 — Proactive administration of amiodarone to patients recovering from a common heart surgery shows ...

Home October 23, 2019
Home
News | Cardiovascular Surgery

October 17, 2019 — W. L. Gore & Associates Inc. will support a new Society for Vascular Surgery (SVS) initiative to ...

Home October 17, 2019
Home
Subscribe Now